Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9H2A9
UPID:
CHST8_HUMAN
Alternative names:
GalNAc-4-O-sulfotransferase 1; N-acetylgalactosamine-4-O-sulfotransferase 1
Alternative UPACC:
Q9H2A9; Q9H3N2
Background:
Carbohydrate sulfotransferase 8, also known as GalNAc-4-O-sulfotransferase 1, plays a crucial role in the modification of glycoproteins. It specifically catalyzes the transfer of sulfate groups to the GalNAc residues of glycoproteins, a process vital for the proper function of various biological systems.
Therapeutic significance:
The protein's involvement in Peeling skin syndrome 3, characterized by skin peeling and potential immune system implications, highlights its therapeutic significance. Understanding the role of Carbohydrate sulfotransferase 8 could open doors to potential therapeutic strategies for this condition.